` ONESOURCE (Onesource Specialty Pharma Ltd) vs BSE Sensex 30 Comparison - Alpha Spread

O
ONESOURCE
vs
B
BSE Sensex 30

Over the past 12 months, ONESOURCE has outperformed BSE Sensex 30, delivering a return of +17% compared to the BSE Sensex 30's +4% growth.

Stocks Performance
ONESOURCE vs BSE Sensex 30

Loading
ONESOURCE
BSE Sensex 30
Add Stock
www.alphaspread.com

Performance Gap
ONESOURCE vs BSE Sensex 30

Loading
ONESOURCE
BSE Sensex 30
Difference
www.alphaspread.com

Performance By Year
ONESOURCE vs BSE Sensex 30

Loading
ONESOURCE
BSE Sensex 30
Add Stock

Competitors Performance
Onesource Specialty Pharma Ltd vs Peers

BSE Sensex 30
ONESOURCE
0KHE
TMO
DHR
207940
Add Stock

Onesource Specialty Pharma Ltd
Glance View

Market Cap
228.8B INR
Industry
Life Sciences Tools & Services

Onesource Specialty Pharma Ltd is a IN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Bangalore, Karnataka and currently employs 525 full-time employees. The company went IPO on 2025-01-24. OneSource Specialty Pharma Limited is an India-based vertically integrated biopharma service company with the capabilities to develop and manufacture complex biologics, biosimilars and vaccines. The company operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO). The firm specializes in prefilled syringes (with or without a safety device), dial and push variable and fixed dose pen injectors, pull push fixed dose pens and autoinjectors. Its integrated services offer comprehensive biologics solutions. The company supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. The firm caters to a variety of capsule shapes and sizes, as well as formulations, traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories.

ONESOURCE Intrinsic Value
74.52 INR
Overvaluation 96%
Intrinsic Value
Price
O
Back to Top